164 related articles for article (PubMed ID: 22014215)
1. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
[TBL] [Abstract][Full Text] [Related]
2. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
3. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
Guin S; Yao HP; Wang MH
Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
7. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
Yao HP; Feng L; Zhou JW; Zhang RW; Wang MH
Am J Cancer Res; 2016; 6(5):937-56. PubMed ID: 27293990
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.
Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH
Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675
[TBL] [Abstract][Full Text] [Related]
11. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
Suthe SR; Yao HP; Weng TH; Wang MH
Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells.
Zeng JY; Sharma S; Zhou YQ; Yao HP; Hu X; Zhang R; Wang MH
Mol Cancer Ther; 2014 Jan; 13(1):37-48. PubMed ID: 24233399
[TBL] [Abstract][Full Text] [Related]
14. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
16. Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.
Chakedis J; French R; Babicky M; Jaquish D; Mose E; Cheng P; Holman P; Howard H; Miyamoto J; Porras P; Walterscheid Z; Schultz-Fademrecht C; Esdar C; Schadt O; Eickhoff J; Lowy AM
Oncotarget; 2016 Jul; 7(29):45959-45975. PubMed ID: 27323855
[TBL] [Abstract][Full Text] [Related]
17. EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA.
Chen J; Liu Q; Xiao J; Du J
Biomacromolecules; 2015 Jun; 16(6):1695-705. PubMed ID: 25988863
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE
Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
[TBL] [Abstract][Full Text] [Related]
20. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
